Can-Fite jumps on positive rheumatoid arthritis treatment results

23-12-2013 GlobesComments (0)

BiotechnologyCan-Fite BioPharma

The share price of Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board: CANFY) rose 24% this afternoon to NIS 1.56 after reporting positive results in a Phase IIb trial for a rheumatoid arthritis treatment. The 12-week placebo-controlled Phase IIb study ...

Read more on Globes

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top